Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)
Anika Therapeutics' (ANIK) quarterly Liabilities from Discontinued Operations came in at 4122000.0 in Q4 2024, down 61.83% year-on-year from 10799000.0 in Q1 2024, and down 61.83% on a QoQ basis from 10799000.0 in Q4 2023.
Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Anika Therapeutics (ANIK) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 4122000.0 in Q4 2024.
- On a quarterly basis, Liabilities from Discontinued Operations fell 61.83% year-over-year to 4122000.0 in Q4 2024; TTM through Dec 2024 was 4122000.0, a 61.83% decrease from a year earlier, with the FY2024 full-year figure at 4122000.0, down 61.83% from the prior year.
- Liabilities from Discontinued Operations for Q4 2024 stood at 4122000.0, down from 10799000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for ANIK reached as high as 10799000.0 in Q4 2023 and fell as low as 4122000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 198.50 Mn | 131.71 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.12 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | 10.80 Mn |
| Dec 31, 2023 | 10.80 Mn |